IRIS
RUMI, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.260
EU - Europa 2.175
AS - Asia 1.560
Continente sconosciuto - Info sul continente non disponibili 11
AF - Africa 10
OC - Oceania 6
SA - Sud America 4
Totale 7.026
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.228
CN - Cina 1.411
IE - Irlanda 868
FI - Finlandia 324
UA - Ucraina 275
DE - Germania 196
IT - Italia 192
SE - Svezia 130
SG - Singapore 115
GB - Regno Unito 75
FR - Francia 37
CA - Canada 32
RO - Romania 24
NL - Olanda 14
BE - Belgio 13
IN - India 12
RU - Federazione Russa 8
EU - Europa 7
AU - Australia 6
CH - Svizzera 6
MU - Mauritius 6
PL - Polonia 5
JP - Giappone 4
LA - Repubblica Popolare Democratica del Laos 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AT - Austria 2
BG - Bulgaria 2
EG - Egitto 2
LV - Lettonia 2
MY - Malesia 2
NG - Nigeria 2
VN - Vietnam 2
XK - ???statistics.table.value.countryCode.XK??? 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BD - Bangladesh 1
CL - Cile 1
CO - Colombia 1
EC - Ecuador 1
ES - Italia 1
GE - Georgia 1
GR - Grecia 1
HK - Hong Kong 1
KG - Kirghizistan 1
LK - Sri Lanka 1
NP - Nepal 1
QA - Qatar 1
SA - Arabia Saudita 1
TR - Turchia 1
TW - Taiwan 1
Totale 7.026
Salva come PNG Salva come JPEG
Città #
Dublin 867
Chandler 643
Jacksonville 423
Nanjing 392
Ashburn 279
Boardman 260
Princeton 168
Nanchang 163
Lawrence 159
Beijing 139
Wilmington 121
Shenyang 116
Hebei 110
Changsha 108
Helsinki 106
Medford 101
New York 95
Jiaxing 91
Ann Arbor 79
Singapore 70
Shanghai 69
Tianjin 61
Hangzhou 58
Milan 37
Woodbridge 29
Norwalk 28
Toronto 28
Seattle 26
Pavia 25
Los Angeles 22
Timisoara 22
Washington 20
Fairfield 15
Brussels 13
Jinan 13
Verona 12
Auburn Hills 10
Falls Church 9
Florence 9
Zhengzhou 9
Guangzhou 8
Ningbo 7
Pune 7
Des Moines 6
Taizhou 6
Monmouth Junction 5
Orange 5
Rome 5
Dearborn 4
Fuzhou 4
Gallarate 4
Reston 4
San Francisco 4
Azzano San Paolo 3
Brugherio 3
Canberra 3
Dallas 3
Fano 3
Fiesole 3
Houston 3
Kunming 3
Lugano 3
Munich 3
Redwood City 3
Saint Paul 3
San Luis Obispo 3
Shijiazhuang 3
Tappahannock 3
Wayne 3
Amsterdam 2
Andover 2
Antony 2
Borås 2
Cairo 2
Chicago 2
Dronten 2
Falkenstein 2
Frankfurt am Main 2
Genoa 2
Gießen 2
Haikou 2
Hanoi 2
Kemerovo 2
Krakow 2
Lagos 2
Lanzhou 2
Leawood 2
London 2
Manchester 2
Monza 2
Navi Mumbai 2
Paderno Dugnano 2
Paris 2
Richmond 2
Santa Clara 2
Sofia 2
Srbica 2
The Bronx 2
Tokyo 2
Vientiane 2
Totale 5.184
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 93
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 81
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 79
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 78
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis 76
High resolution genome-wide array-comparative genomic hybridization in splenic marginal zone B-cell lymphoma 74
Blast phase of essential thrombocythemia: A single center study. 73
An insidious presentation of splenic marginal zone lymphoma 72
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 72
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis 71
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 70
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients 70
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 69
JAK2 (V617F) mutation in healthy individuals 68
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. 67
Peripheral intraneutrophil diplococci in a case of meningococcemia. 66
Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. 65
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms 65
Clinical significance of somatic mutation in unexplained blood cytopenia 65
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. 64
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment 62
Cardiovascular events and intensity of treatment in polycythemia vera. 61
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 60
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. 60
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 59
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients 59
Role of the molecular staging and response in the management of follicular lymphoma patients 58
Familial chronic myeloproliferative disorders: the state of the art 58
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. 58
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. 58
Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. 58
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 58
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 58
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms 57
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 57
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders 57
A novel germline JAK2 mutation in familial myeloproliferative neoplasms. 57
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients 57
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. 56
Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms. 56
Allelic imbalance in CALR somatic mutagenesis 56
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin 56
Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. 56
Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms. 55
Clinical relevance of JAK2 (V617F) mutant allele burden 55
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients. 54
Clinical significance of genetic aberrations in secondary acute myeloid leukemia. 54
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm 53
Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. 52
Advances in understanding the pathogenesis of familial myeloproliferative neoplasms 52
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. 51
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms 51
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. 51
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. 50
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 50
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 P95-mutated neoplasms 50
LIVER BIOPSY DURING SPLENECTOMY REVEALS THAT SPLENIC MARGINAL ZONE LYMPHOMA IS OFTEN AN HEPATO-SPLENIC DISEASE 49
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. 49
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib 49
Splenic marginal zone B-cell lymphoma in a HIV-positive patient: a case report 48
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. 48
Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies. 48
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 48
Splenic marginal zone lymphoma: clinical clustering of immunoglobulin heavy chain repertoires 48
Mutational status of myeloproliferative neoplasms. 47
Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. 47
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 47
Improving survival trends in primary myelofibrosis: an international study. 47
Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases 46
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) 46
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation 46
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression 46
Platelet count predicts driver mutations’ co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis 46
Mutations and prognosis in primary myelofibrosis 45
Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia 45
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment 44
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 44
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. 44
JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms. 43
Myelofibrotic transformation in essentialthrombocythemia. Author reply 43
Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene 43
Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms 43
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. 43
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. 43
Diagnosis and management of prefibrotic myelofibrosis. 43
LNK mutations in familial myeloproliferative neoplasms. 43
Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. 42
Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia 42
Pregnancy complications predict thrombotic events in young women with essential thrombocythemia 41
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms 41
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. 41
Somatic mutations of calreticulin in myeloproliferative neoplasms 41
HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia 39
How I treat essential thrombocythemia. 39
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. 38
Masked polycythemia vera diagnosed according to WHO and BCSH classification 38
A prognostic model to predict survival in 867 WHO-defined essential thrombocythemia at diagnosis: a study by the IWG-MRT. 37
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. 37
Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. 35
Leukemic transformation of polycythemia vera: a single center study of 23 patients 35
Totale 5.365
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.995
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.995
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020444 0 0 0 50 3 60 18 95 27 146 41 4
2020/2021605 74 48 13 62 4 62 10 106 53 89 66 18
2021/2022693 9 4 23 11 17 38 6 38 33 38 115 361
2022/20232.091 223 118 21 135 204 169 1 100 992 13 87 28
2023/20241.055 119 170 55 70 96 302 27 66 10 22 76 42
2024/2025380 66 209 72 33 0 0 0 0 0 0 0 0
Totale 7.373